Information Provided By:
Fly News Breaks for June 6, 2016
MNK
Jun 6, 2016 | 07:11 EDT
Goldman analyst Stephan Stewart initiated Mallinckrodt with a Neutral and $73 price target. The analyst said Mallinckrodt's low organic growth, high product concentration, ongoing generic pressures, and durability concerns of its largest branded drug, Acthar, keeps him on the sidelines.
News For MNK From the Last 2 Days
There are no results for your query MNK